[Federal Register Volume 85, Number 233 (Thursday, December 3, 2020)]
[Notices]
[Pages 78148-78149]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26626]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Subcutaneous Drug Development & Delivery 
Consortium, Inc.

    Notice is hereby given that, on October 26, 2020, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug 
Development & Delivery Consortium, Inc. (``Subcutaneous Drug 
Development & Delivery Consortium, Inc.'') has filed written 
notifications simultaneously with the Attorney General and the Federal 
Trade Commission disclosing (1) the identities of the parties to the 
venture and (2) the nature and objectives of the venture. The 
notifications were filed for the purpose of invoking the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances.
    Pursuant to Section 6(b) of the Act, the identity of the parties to 
the venture are: Eli Lilly and Company, Indianapolis, IN; Halozyme, 
Inc., San Diego, CA; Bristol Myers Squibb, New Brunswick, NJ; 
AstraZeneca, San Francisco, CA; and Amgen Inc., Thousand Oaks, CA. The 
general area of Subcutaneous Drug Development & Delivery Consortium, 
Inc.'s planned activity is (a) transform patient care and improve 
patient outcomes by identifying and addressing key gaps, unmet needs 
and actionable issues in the dynamic subcutaneous (``SC'') drug 
delivery and development landscape, including through research, 
publication of industry analyses, and the

[[Page 78149]]

development of SC-related manuscripts, models, standards and other 
guidance materials (collectively, ``Guidance''); (b) provide a venue 
for reviewing, developing, maintaining and supporting the Guidance; (c) 
promote the Guidance worldwide; (d) provide for testing and conformity 
assessment of implementations in order to ensure and/or facilitate 
compliance with Guidance; (e) operate a branding program based upon 
distinctive trademarks to create high customer awareness of, demand 
for, and confidence in the Guidance, and products or services designed 
in compliance therewith; and (f) undertake such other activities as may 
from time to time be appropriate to further the purposes and achieve 
the goals set forth above.
    Membership in Subcutaneous Drug Development & Delivery Consortium, 
Inc. remains open and Subcutaneous Drug Development & Delivery 
Consortium, Inc. intends to file additional written notifications 
disclosing all changes in membership.

Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2020-26626 Filed 12-2-20; 8:45 am]
BILLING CODE 4410-11-P